EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bidirectional pharmacokinetic drug interactions between olaparib and metformin

Joanna Stanisławiak-Rudowicz iD, Agnieszka Karbownik iD, Danuta Szkutnik-Fiedler iD, Filip Otto iD, Tomasz Grabowski iD, Anna Wolc iD, Edmund Grześkowiak iD, Edyta Szałek iD

Cancer Chemotherapy and Pharmacology · 2024

DOI: 10.1007/s00280-023-04591-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2024. Verfasst von Joanna Stanisławiak-Rudowicz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Biopharmacy, Poznań University of Medical Sciences, Rokietnicka 3, 60-806, Poznań, Poland. jstanislawiak@ump.edu.…. Hauptthemen laut MEDLINE: Metformin, Diabetes Mellitus, Type 2, Phthalazines, Piperazines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Olaparib is a PARP (poly-ADP-ribose polymerase) inhibitor used for maintenance therapy in BRCA-mutated cancers. Metformin is a first-choice drug used in the treatment of type 2 diabetes. Both drugs are commonly co-administered to oncologic patients with add-on type 2 diabetes mellitus. Olaparib is metabolized by the CYP3A4 enzyme, which may be inhibited by metformin through the Pregnane X Receptor . In vitro studies have shown that olaparib inhibits the following metformin transporters: OCT1, MATE1, and MATE2K. The aim of the study was to assess the influence of ‘the perpetrator drug’ on the pharmacokinetic (PK) parameters of ‘the victim drug’ after a single dose. To evaluate the effect, the AUC 0→∞ (area under the curve) ratio was determined (the ratio between AUC 0→∞ in the presence of the perpetrator and AUC 0→∞ without the presence of the perpetrator).

Methods

Male Wistar rats were assigned to three groups (eight animals in each group), which were orally administered: metformin and olaparib (I MET+OLA ), vehiculum with metformin (II MET ), and vehiculum with olaparib (III OLA ). Blood samples were collected after 24 h. HPLC was applied to measure the concentrations of olaparib and metformin. The PK parameters were calculated in a non-compartmental model.

Results

Metformin did not affect the olaparib PK parameters. The AUC 0→∞ I MET+OLA /III OLA ratio was 0.99. Olaparib significantly increased the metformin C max (by 177.8%), AUC 0→t (by 159.8%), and AUC 0→∞ (by 74.1%). The AUC 0→∞ I MET+OLA /II MET ratio was 1.74.

Conclusions

A single dose of metformin did not affect the PK parameters of olaparib, nor did it inhibit the olaparib metabolism, but olaparib significantly changed the metformin pharmacokinetics, which may be of clinical importance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminDiabetes Mellitus, Type 2PhthalazinesPiperazinesHumansAnimalsRatsMaleRats, WistarDrug InteractionsArea Under Curve

Stichwörter der Autor:innen

Drug–drug interactionsMetforminOlaparibPharmacokinetics

Substanzen

MetforminolaparibPhthalazinesPiperazines

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Biopharmacy, Poznań University of Medical Sciences, Rokietnicka 3, 60-806, Poznań, Poland. jstanislawiak@ump.edu.pl.
  • Poznań University Clinical Hospital, Szamarzewskiego 84/86, 60-569, Poznań, Poland. jstanislawiak@ump.edu.pl.
  • Department of Clinical Pharmacy and Biopharmacy, Poznań University of Medical Sciences, Rokietnicka 3, 60-806, Poznań, Poland.
  • Department of Inorganic Chemistry, Faculty of Pharmacy, Medical University of Gdańsk, M. Skłodowskiej-Curie 3a, 80-210, Gdańsk, Poland.
  • Department of Animal Science, Iowa State University, 239E Kildee Hall, Ames, IA, 50011, USA.
  • Hy-Line International, 2583 240th Street, Dallas Center, IA, 50063, USA.

ORCID-Profile: Joanna Stanisławiak-Rudowicz, Agnieszka Karbownik, Danuta Szkutnik-Fiedler, Filip Otto, Tomasz Grabowski, Anna Wolc, Edmund Grześkowiak, Edyta Szałek

Förderung

  • Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

Zitieren

APA

Stanisławiak-Rudowicz, J., Karbownik, A., Szkutnik-Fiedler, D., Otto, F., Grabowski, T., Wolc, A., Grześkowiak, E., & Szałek, E. (2024). Bidirectional pharmacokinetic drug interactions between olaparib and metformin. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-023-04591-y

Vancouver

Stanisławiak-Rudowicz J, Karbownik A, Szkutnik-Fiedler D, Otto F, Grabowski T, Wolc A, et al. Bidirectional pharmacokinetic drug interactions between olaparib and metformin. Cancer Chemotherapy and Pharmacology. 2024. doi:10.1007/s00280-023-04591-y

BibTeX
@article{StanisawiakRudowicz2024,
  author = {Stanisławiak-Rudowicz, Joanna and Karbownik, Agnieszka and Szkutnik-Fiedler, Danuta and Otto, Filip and Grabowski, Tomasz and Wolc, Anna and Grześkowiak, Edmund and Szałek, Edyta},
  title = {Bidirectional pharmacokinetic drug interactions between olaparib and metformin},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2024},
  doi = {10.1007/s00280-023-04591-y}
}
Kostenlos starten →